Allogene Therapy Clears Cancer in Phase 2 Trial

Allogene Therapeutics said on April 13, 2026, that early results from its Phase 2 ALPHA3 study show its off-the-shelf CAR-T cell therapy, cema-cel, eliminated minimal residual disease (MRD) in more than half of evaluated lymphoma patients. The company described the update as an initial data release focused on how well cema-cel reduced remaining lymphoma cells after first-line chemotherapy.

The dataset covered 24 patients in total, split between a cema-cel arm and a control arm. Allogene reported that seven of 12 patients who received cema-cel were MRD-negative at day 45, compared with two of 12 patients in the control group. The company said the resulting 41.6% difference in MRD eradication exceeded a clinically meaningful benchmark of 25% to 30%.

Allogene also highlighted changes in circulating lymphoma DNA at the same timepoint. It said cema-cel reduced circulating lymphoma DNA by an average of 97.7% at day 45, while the control arm showed a 26.6% increase. The company presented these measures as evidence of a substantial reduction in lingering disease signals following initial chemotherapy.

On safety and care setting, Allogene said cema-cel did not trigger cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, which are commonly cited severe side effects associated with traditional autologous CAR-T therapies. The company added that 10 of the 12 patients treated with cema-cel were managed in outpatient settings after treatment. Allogene framed this as a practical difference in how patients may be monitored and supported following therapy.

Looking ahead, Allogene said it expects to finish enrolling patients in the ALPHA3 trial by late 2027. The company said key event-free survival readouts are expected in mid-2027 and mid-2028. It also stated that, if outcomes are successful, cema-cel could become the first donor-derived CAR-T therapy approved by the FDA.

For markets and policymakers, the update places attention on whether donor-derived, off-the-shelf CAR-T approaches can show strong disease-clearance signals alongside a safety profile that supports outpatient management. At the same time, the company’s timeline underscores that the current release is early and based on a small number of patients, with longer-term endpoints still pending.